Related Experiment Videos
The activity of azithromycin in animal models of infection
1Department of Genetics and Microbiology, University of Geneva Medical School, Switzerland.
Abstract:
High and prolonged tissue levels accompanied by low serum concentrations are a feature of azithromycin, an azalide antibiotic. It has a broad spectrum of activity against gram-positive and gram-negative microorganisms and several intracellular pathogens. A number of animal models of localised infection have been developed which demonstrate that the efficacy of azithromycin correlates with its extravascular pharmacokinetics and not with blood levels. In many instances, because of high tissue bioavailability, azithromycin has better in vivo efficacy than comparative agents, despite a similar or higher minimum inhibitory concentration. Additionally, the extravascular kinetics of azithromycin are associated with bactericidal activity against pathogens such as Staphylococcus aureus, Streptococcus pneumoniae and Escherichia coli. Intracellular pathogens are susceptible to azithromycin and it is believed that the agent penetrates and remains within host cells infected by organisms including Mycobacterium avium, Legionella pneumophila and Borrelia burgdorferi. This paper reviews the in vivo efficacy of azithromycin and standard agents in animal models of infection, especially those involving intracellular pathogens.
Insights
Azithromycin, an antibiotic, shows high tissue levels and efficacy against various pathogens, including intracellular ones. Its effectiveness in animal models correlates with tissue concentration, not blood levels, highlighting its pharmacokinetic advantage.
Area of Science:
- Pharmacology
- Microbiology
- Infectious Diseases
Background:
- Azithromycin, an azalide antibiotic, is known for high and prolonged tissue concentrations with low serum levels.
- It exhibits broad-spectrum activity against Gram-positive, Gram-negative, and intracellular pathogens.
Purpose of the Study:
- To review the in vivo efficacy of azithromycin compared to standard agents in animal infection models.
- To specifically examine efficacy against intracellular pathogens.
Main Methods:
- Review of animal models of localized infection.
- Correlation analysis between azithromycin's extravascular pharmacokinetics and in vivo efficacy.
- Assessment of efficacy against specific pathogens like Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Mycobacterium avium, Legionella pneumophila, and Borrelia burgdorferi.
Main Results:
- Azithromycin's efficacy in animal models correlates with extravascular pharmacokinetics, not serum concentrations.
- High tissue bioavailability contributes to superior in vivo efficacy compared to other agents, even with similar or higher minimum inhibitory concentrations.
- Extravascular kinetics are linked to bactericidal activity against key pathogens, including intracellular ones.
Conclusions:
- Azithromycin demonstrates significant in vivo efficacy driven by its pharmacokinetic profile, particularly high tissue penetration and retention.
- The antibiotic is effective against a range of pathogens, including challenging intracellular bacteria.
- Animal models support azithromycin's utility in treating localized infections, especially those involving intracellular pathogens.